Prostatic Neoplasms, Castration-Resistant Not Yet Recruiting Phase 2 Trials for Abiraterone (DB05812)

IndicationStatusPhase
DBCOND0001230 (Prostatic Neoplasms, Castration-Resistant)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs